Dapsone for Refractory Gastrointestinal Symptoms in Children With Immunoglobulin A Vasculitis

Pediatrics. 2022 Sep 1;150(3):e2021055884. doi: 10.1542/peds.2021-055884.

Abstract

Immunoglobulin A vasculitis (IgAV) is a systemic small-vessel vasculitis. Although corticosteroids (CS) are the primary treatment for gastrointestinal manifestations associated with IgAV, some patients develop refractory or recurrent symptoms such as vomiting and abdominal pain despite CS treatment. Dapsone, a synthetic sulfone antimicrobial, has been used to treat cutaneous purpura in IgAV, but few authors have reported its use for refractory gastrointestinal symptoms. In this retrospective observational study, we describe results in 7 children with IgAV who were treated with dapsone for abdominal pain resistant to CS. Dapsone rapidly relieved abdominal pain in all 7 patients, who then were tapered off CS without relapse. Side effects of mild methemoglobinemia and hemolysis appeared to be manageable with planned monitoring and dose adjustment; a single patient who discontinued dapsone had fatigue and hypoxia associated with methemoglobinemia. No side effects were life-threatening. Dapsone may be considered as a therapeutic option for gastrointestinal symptoms refractory to CS in children with IgAV.

Publication types

  • Observational Study

MeSH terms

  • Abdominal Pain / drug therapy
  • Adrenal Cortex Hormones
  • Child
  • Dapsone / adverse effects
  • Gastrointestinal Diseases* / chemically induced
  • Gastrointestinal Diseases* / drug therapy
  • Humans
  • IgA Vasculitis*
  • Immunoglobulin A
  • Methemoglobinemia* / chemically induced
  • Methemoglobinemia* / drug therapy
  • Vasculitis* / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Immunoglobulin A
  • Dapsone